Literature DB >> 25331204

The thrill of success: central arterial-venous anastomosis for hypertension.

Marat Fudim1, Alice Stanton, Paul A Sobotka, Eamon Dolan, Henry Krum.   

Abstract

Excess blood pressure remains the most important risk factor for cardiovascular and renal disease. Poly pharmacy has been proved safe and effective under clinical trial circumstances; however, the majority of patients fail to sustain pharmaceutical persistence and adherence. The opportunity to offer patients a treatment or device in addition or perhaps instead of drug therapy alone may significantly broaden the options for patients and allow greater success in hypertensive therapy. In this review, we examine the potential of a fixed-volume central arterial-venous anastomosis to reduce blood pressure in hypertensive patients, review possible mechanisms by which the anastomosis may reduce blood pressure, and consider the unique clinical trial opportunities posed by this therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25331204     DOI: 10.1007/s11906-014-0497-x

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  31 in total

1.  Effects of arteriovenous fistula on clinical, laboratory and echocardiographic findings in renal allograft recipients.

Authors:  Numan Gorgulu; Yasar Caliskan; Berna Yelken; Faruk Akturk; Aydin Turkmen
Journal:  Int J Artif Organs       Date:  2011-10       Impact factor: 1.595

2.  Effects of the creation of arteriovenous fistula for hemodialysis on cardiac function and natriuretic peptide levels in CRF.

Authors:  Yoshio Iwashima; Takeshi Horio; Yoichi Takami; Takashi Inenaga; Toshio Nishikimi; Shuichi Takishita; Yuhei Kawano
Journal:  Am J Kidney Dis       Date:  2002-11       Impact factor: 8.860

3.  Global burden of hypertension: analysis of worldwide data.

Authors:  Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

4.  Cardiac effects of persistent hemodialysis arteriovenous access in recipients of renal allograft.

Authors:  J J De Lima; M L Vieira; L J Molnar; C J Medeiros; L E Ianhez; E M Krieger
Journal:  Cardiology       Date:  1999       Impact factor: 1.869

5.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

6.  Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients.

Authors:  Sayed H Naderi; Jonathan P Bestwick; David S Wald
Journal:  Am J Med       Date:  2012-06-27       Impact factor: 4.965

7.  The 6-min walk distance: change over time and value as a predictor of survival in severe COPD.

Authors:  V M Pinto-Plata; C Cote; H Cabral; J Taylor; B R Celli
Journal:  Eur Respir J       Date:  2004-01       Impact factor: 16.671

Review 8.  Mechanisms of chronic heart failure development in end-stage renal disease patients on chronic hemodialysis.

Authors:  J Malík; V Tuka; M Mokrejšová; R Holaj; V Tesar
Journal:  Physiol Res       Date:  2008-11-04       Impact factor: 1.881

Review 9.  Pulmonary hypertension in dialysis patients.

Authors:  George Kosmadakis; Didier Aguilera; Odette Carceles; Enrique Da Costa Correia; Ioannis Boletis
Journal:  Ren Fail       Date:  2013-02-14       Impact factor: 2.606

Review 10.  COPD and PE: a clinical dilemma.

Authors:  Teng Moua; Kenneth Wood
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.